Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ImageneBio, Inc. (IMA)

ImageneBio Q2 net loss widens to $10.2 million as cash stands at $136.2 million

Negative Impact 3 of 5 earnings Written later

ImageneBio reported a second-quarter 2026 net loss of $10.2 million, or $0.63 per share, up from a net loss of $7.6 million a year earlier, with no license revenue in either period. The company said its $136.2 million in cash and marketable securities should fund planned operations into the first quarter of 2028, and that the Phase 2b ADAPTIVE trial of olevaprubart in atopic dermatitis continues under an amended protocol with topline data expected in the fourth quarter of 2027.

Key points

  • Net loss was $10.2 million for the quarter ended June 30, 2026, versus $7.6 million in the same quarter of 2025; G&A expenses rose to $5.1 million from $1.7 million.
  • Loss per share was $0.63, compared with $4.46 a year earlier; the 2025 figure reflected a smaller share count and $3.1 million in preferred stock accretion.
  • Cash, cash equivalents and marketable securities totaled $136.2 million as of June 30, 2026, after a $30 million private placement closed in April 2026.
  • Yanina Grant-Huerta was appointed Chief Financial Officer and Matt Robbins General Counsel; the ADAPTIVE trial's data monitoring committee recommended the study proceed unchanged on July 23, 2026.

The filing

CompanyImageneBio, Inc. (IMA)
Form8-K, current report
Filed with the SECAug 5, 2026, 8:05 AM ET
Accession number0001193125-26-333912

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.